Boehringer Ingelheim   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Ingelheim am Rhein Germany (1885)

Organization Overview

First Clinical Trial
1990
NCT02177370
First Marketed Drug
1956
phenmetrazine (preludin)
First NDA Approval
1956
phenmetrazine (preludin)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BEN VENUE | B.I. Pharmaceuticals,Inc./Ridgefield | BI Pharma Ges mbH Wien | Boehringer Ingelheim | Boehringer-Ingelheim | BOEHRINGER INGELHEIM | Boehringer Ingelheim BV/Alkmaar | Boehringer Ingelheim (Canada) LTD | Boehringer Ingelheim KG | Boehringer Ingelheim Ltd./Bracknell | Boehringer Ingelheim Shanghai | Boeringer Ingelheim | Nippon Boehringer Ingelheim Co., Ltd.